Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
10.11.2018

Report: Heartburn Drugs Linked to Kidney Damage

By Brian Lynch
You Should Know, For Consumers

heartburn drugs linked to kidney damage

Chronic heartburn sufferers know how severe and uncomfortable the condition can be, with symptoms that can make eating, sleeping, and other daily routines significantly more challenging. Heartburn drugs, also known as proton pump inhibitors (PPIs), are often used to provide relief by reducing gastric acid. But a new study has found that the treatment may be worse than the illness in the long run, as popular heartburn drugs have been linked to kidney damage.

The study, published in the journal Kidney International, found a link between taking popular heartburn drugs such as Prilosec, Nexium, and others over a prolonged period of time with serious kidney problems, including kidney failure. Researchers studied 125,596 PPI users over the course of five years. They found that PPI users were at a higher risk for chronic kidney diseases and acute kidney injuries than use of H2 blockers like Zantac or Pepcid.

Even more troubling, the study found that more than half of the patients who develop chronic kidney damage while taking PPIs do not develop noticeable warning signs, meaning patients with declining kidney function may be unaware of their condition.

“It’s a silent disease, in the sense that it erodes kidney function very minimally and very gradually over time,” said Ziyad Al-Aly, the senior author of the study and assistant professor of medicine at Washington University School of Medicine.

Al-Aly stressed that while kidney problems remain rare in those taking PPIs (a 20 percent increase in developing chronic kidney disease on average) even a small potential risk increase can be considered serious with a drug taken by millions of people. According to an NPR report in 2016, an estimated 15 million Americans use PPIs to treat heartburn, while millions more use over-the-counter versions without being under a doctor’s care.

Disclaimer: This article has been prepared for general information purposes and does not constitute medical or legal advice, nor does it imply an attorney-client relationship or contract with Wexler Wallace.

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP